LIBRETTO-432 Trial at ASCO 2026 Plenary Session: Adjuvant Selpercatinib in RET Fusion-Positive NSCLC

oncodaily - LIBRETTO-432 Trial was presented during ASCO 2026 by Jonathan W. Goldman, MD, as a global, multicenter, phase 3, double-blind, randomized, placebo-controlled study evaluating adjuvant selpercatinib in patients with early-stage RET […]

AI Summary: At ASCO26 plenary, LIBRETTO‑432 data show adjuvant selpercatinib markedly prolongs event‑free survival and slashes recurrence risk for patients with stage II–IIIA RET fusion–positive non‑small cell lung cancer after curative treatment. The findings support a new standard for this rare genetic subgroup and press the case for routine genomic testing.

#pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch #clinicaltrials #genetics #diagnostics

Adjuvant Selpercatinib Prolongs EFS Among Patients with Stage II or IIIA RET Fusion-Positive NSCLC

57 min / esmo

Targeted therapy reduces risk of lung cancer recurrence by 83% in rare genetic subtype

10 hrs / medicalxpress

Narjust Florez: Practice-Changing LIBRETTO-432 Data at ASCO26

16 hrs / oncodaily

LIBRETTO-432 Trial at ASCO 2026 Plenary Session: Adjuvant Selpercatinib in RET Fusion-Positive NSCLC

34 hrs / oncodaily

StackHealth RSS

You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Wildlife, Pediatric Oncology, Reproductive Health, Hearing Loss and look for the RSS link.

StackHealth Time Machine

More StackHealth